Merus (MRUS) Earnings Call Presentation

Petosemtamab Clinical Trial Results in HNSCC - In 2L+ r/m HNSCC, petosemtamab monotherapy showed a confirmed overall response rate (ORR) of 36% (27 out of 75 patients) [24, 25] - Petosemtamab with pembrolizumab in 1L PD-L1+ r/m HNSCC achieved a confirmed overall response rate (ORR) of 63% [53, 58] - The median progression-free survival (mPFS) for petosemtamab with pembrolizumab in 1L PD-L1+ r/m HNSCC was 9 months, and the overall survival (OS) rate at 12 months was 79% [55, 58] Safety and Tolerability - In the petosemtamab monotherapy trial (1500 mg Q2W), all 82 patients experienced at least one treatment-emergent adverse event (TEAE), with 59% experiencing Grade ≥3 TEAEs [29, 30] - When petosemtamab was administered with pembrolizumab, all 45 patients experienced at least one TEAE, with 60% experiencing Grade ≥3 TEAEs [51] - Infusion-related reactions (IRRs) occurred in 38% of patients receiving petosemtamab with pembrolizumab, with 7% being Grade 3 [40, 52] Market Opportunity and Pipeline - Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer [65, 79] - Estimated sales for HNSCC and CRC in 2024 are $4 billion and $7.1 billion, respectively [73] - The company has patents expiring no earlier than October 2038 related to petosemtamab and a topoisomerase inhibitor [64]